A citation-based method for searching scientific literature

Kenneth Cusi, Beverly Orsak, Fernando Bril, Romina Lomonaco, Joan Hecht, Carolina Ortiz-Lopez, Fermin Tio, Jean Hardies, Celia Darland, Nicolas Musi, Amy Webb, Paola Portillo-Sanchez. Ann Intern Med 2016
Times Cited: 507







List of co-cited articles
1992 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
62

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
944
56

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
53

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
357
53

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Renata Belfort, Stephen A Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin Tio, Joseph Pulcini,[...]. N Engl J Med 2006
46

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
41


Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome,[...]. Lancet 2019
488
33

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
30

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
Guruprasad P Aithal, James A Thomas, Philip V Kaye, Adam Lawson, Stephen D Ryder, Ian Spendlove, Andrew S Austin, Jan G Freeman, Linda Morgan, Jonathan Webber. Gastroenterology 2008
487
30

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Fernando Bril, Diane M Biernacki, Srilaxmi Kalavalapalli, Romina Lomonaco, Sreevidya K Subbarayan, Jinping Lai, Fermin Tio, Amitabh Suman, Beverly K Orsak, Joan Hecht,[...]. Diabetes Care 2019
134
29

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
636
26

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Zobair M Younossi, Pegah Golabi, Leyla de Avila, James Minhui Paik, Manirath Srishord, Natsu Fukui, Ying Qiu, Leah Burns, Arian Afendy, Fatema Nader. J Hepatol 2019
647
25

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
24

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Sven M Francque, Pierre Bedossa, Vlad Ratziu, Quentin M Anstee, Elisabetta Bugianesi, Arun J Sanyal, Rohit Loomba, Stephen A Harrison, Rozalina Balabanska, Lyudmila Mateva,[...]. N Engl J Med 2021
90
25

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mustafa R Bashir, Cynthia D Guy, Rong Zhou, Cynthia A Moylan, Juan P Frias, Naim Alkhouri, Meena B Bansal, Seth Baum, Brent A Neuschwander-Tetri,[...]. Lancet 2019
224
22

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino. JAMA Intern Med 2017
202
21

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Samer Gawrieh, Mazen Noureddin, Nicole Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V Kowdley, Michelle Lai, Eugene Schiff, Deven Parmar,[...]. Hepatology 2021
58
36

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Jan W Eriksson, Per Lundkvist, Per-Anders Jansson, Lars Johansson, Mats Kvarnström, Linda Moris, Tasso Miliotis, Gun-Britt Forsberg, Ulf Risérus, Lars Lind,[...]. Diabetologia 2018
173
20

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill,[...]. Diabetes Care 2018
268
19

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
19

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Parambir S Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr,[...]. Hepatology 2017
876
18

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
18

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
17

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray,[...]. Lancet 2005
17

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
17

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
16

Treatment of NAFLD with diet, physical activity and exercise.
Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell. J Hepatol 2017
527
16

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Stephen A Harrison, Naim Alkhouri, Beth A Davison, Arun Sanyal, Christopher Edwards, Jerry R Colca, Bo Hyun Lee, Rohit Loomba, Kenneth Cusi, Orville Kolterman,[...]. J Hepatol 2020
100
16

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, Natalie Bzowej, Raj Vuppalanchi, Ziad Younes, Anita Kohli, Shiv Sarin, Stephen H Caldwell, Naim Alkhouri,[...]. J Hepatol 2020
171
16

Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Masanori Shimizu, Kunihiro Suzuki, Kanako Kato, Teruo Jojima, Toshie Iijima, Toshimitsu Murohisa, Makoto Iijima, Hidehiro Takekawa, Isao Usui, Hideyuki Hiraishi,[...]. Diabetes Obes Metab 2019
156
15


Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
Kenneth Cusi, Fernando Bril, Diana Barb, David Polidori, Sue Sha, Atalanta Ghosh, Kristin Farrell, Nishanth E Sunny, Srilaxmi Kalavalapalli, Jeremy Pettus,[...]. Diabetes Obes Metab 2019
77
19

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
990
15

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.
Stephen A Harrison, Peter J Ruane, Bradley L Freilich, Guy Neff, Rashmee Patil, Cynthia A Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J Tillman,[...]. Nat Med 2021
51
29

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Vlad Ratziu, Arun Sanyal, Stephen A Harrison, Vincent Wai-Sun Wong, Sven Francque, Zachary Goodman, Guruprasad P Aithal, Kris V Kowdley, Star Seyedkazemi, Laurent Fischer,[...]. Hepatology 2020
130
15

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
Guillaume Lassailly, Robert Caiazzo, David Buob, Marie Pigeyre, Hélène Verkindt, Julien Labreuche, Violeta Raverdy, Emmanuelle Leteurtre, Sébastien Dharancy, Alexandre Louvet,[...]. Gastroenterology 2015
442
15

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.
Kittichai Promrat, David E Kleiner, Heather M Niemeier, Elizabeth Jackvony, Marie Kearns, Jack R Wands, Joseph L Fava, Rena R Wing. Hepatology 2010
797
14

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Giovanni Targher, Christopher D Byrne, Amedeo Lonardo, Giacomo Zoppini, Corrado Barbui. J Hepatol 2016
664
14

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.
Sabine Kahl, Sofiya Gancheva, Klaus Straßburger, Christian Herder, Jürgen Machann, Hisayuki Katsuyama, Stefan Kabisch, Elena Henkel, Stefan Kopf, Merit Lagerpusch,[...]. Diabetes Care 2020
97
14


Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Rohit Loomba, Mazen Noureddin, Kris V Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H Caldwell, Zachary Goodman,[...]. Hepatology 2021
77
18

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Scott L Friedman, Vlad Ratziu, Stephen A Harrison, Manal F Abdelmalek, Guruprasad P Aithal, Juan Caballeria, Sven Francque, Geoffrey Farrell, Kris V Kowdley, Antonio Craxi,[...]. Hepatology 2018
393
13

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Gastroenterology 2019
534
13

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Keyur Patel, Stephen A Harrison, Magdy Elkhashab, James F Trotter, Robert Herring, Sergio E Rojter, Zeid Kayali, Vincent Wai-Sun Wong, Susan Greenbloom, Saumya Jayakumar,[...]. Hepatology 2020
124
13

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
13

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias, Rolf Hultcrantz. Hepatology 2015
13

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Norbert Stefan, Hans-Ulrich Häring, Kenneth Cusi. Lancet Diabetes Endocrinol 2019
368
12

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Vlad Ratziu, Philippe Giral, Sophie Jacqueminet, Fréderic Charlotte, Agnès Hartemann-Heurtier, Lawrence Serfaty, Philippe Podevin, Jean-Marc Lacorte, Carole Bernhardt, Eric Bruckert,[...]. Gastroenterology 2008
449
12

Once-Weekly Semaglutide in Adults with Overweight or Obesity.
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden,[...]. N Engl J Med 2021
437
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.